CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2026年3月1日～2026年3月7日の間に収集した論文情報を追加しました。

  1. Venous Thromboembolism with Combined Oral Contraceptives Based on Estrogen and Progestin Content: A disproportionality analysis of the United States Food and Drug Administration Adverse Event Reporting System database.

  経口避妊薬の成分別静脈血栓塞栓症リスクをFAERSで解析。

  対象DB：FAERS

  2. Long-term safety evaluation of mirtazapine: A real-world pharmacovigilance study based on the FAERS database.

  ミルタザピンの長期安全性をFAERSに基づきリアルワールド解析。

  対象DB：FAERS

  3. Unveiling the risk: A comprehensive analysis of drug-induced aphthous ulcers using real-world data from FAERS.

  薬剤性アフタ性潰瘍のリスクをFAERSデータから包括的に解析。

  対象DB：FAERS

  4. Data mining and analysis of adverse drug events of propofol in the general population and the elderly based on the US Food and Drug Administration Adverse Event Reporting System.

  プロポフォールの副作用を一般人と高齢者で比較しFAERS解析。

  対象DB：FAERS

  5. Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database.

  キノロン系抗菌薬とパニック障害のリスクをFAERS等で解析。

  対象DB：CVAR,FAERS

  6. Cutaneous adverse events associated with Rybrevant based on FDA adverse event reporting system (FAERS) database from 2021 to 2024.

  2021-24年のFAERSからRybrevantの皮膚副作用を解析。

  対象DB：FAERS

  7. Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database.

  リサンキズマブとグセルクマブの安全性をFAERSで比較解析。

  対象DB：FAERS

  8. Appendicitis and multiple sclerosis disease-modifying therapies: a disproportionality analysis of the FDA adverse event reporting system.

  多発性硬化症治療薬と虫垂炎の関連をFAERSで不均衡解析。

  対象DB：FAERS

  9. Assessing safety trends of withdrawn medications: A data-driven pharmacovigilance approach using growth models.

  販売中止薬の安全性傾向を成長モデルを用いてデータ駆動型解析。

  対象DB：FAERS

  10. Descriptive analysis of anaphylactic events reported in the FDA Adverse Event Reporting System (FAERS).

  FAERSに報告されたアナフィラキシー事象の記述的解析。

  対象DB：FAERS

  11. Drug-related proteinuria: a vigilance analysis based on the FAERS database.

  薬剤性蛋白尿のリスクをFAERSデータベースに基づき解析。

  対象DB：FAERS

  12. Disproportionality analysis of adverse events associated with degarelix: a real-world study from the FDA Adverse Event Reporting System (FAERS) database.

  デガレリクスの副作用をFAERSデータからリアルワールド解析。

  対象DB：FAERS

  13. Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system.

  INSTI関連の体重増加および糖脂質代謝異常をFAERSで解析。

  対象DB：FAERS

  14. Association of GnRH agonists with depression and suicide/self-injury: a FAERS pharmacovigilance study.

  GnRHアゴニストと抑うつ・自傷リスクの関連をFAERSで解析。

  対象DB：FAERS

  15. A real-world study of adverse event profiles associated with the four key components of antibody-drug conjugates based on the FAERS database.

  ADCの4つの主要構成要素に関する副作用プロファイルを解析。

  対象DB：FAERS

  16. A real-world study of ublituximab based on the WHO-VigiAccess and U.S. food and drug administration's adverse event reporting system databases.

  ウブリツキシマブの安全性をVigiAccessとFAERSで解析。

  対象DB：FAERS

  17. Thromboembolic adverse events associated with TPO-RA in ITP treatment: a pharmacovigilance analysis of the FDA Adverse Event Reporting System.

  ITP治療薬TPO-RAの血栓塞栓症リスクをFAERSで解析。

  対象DB：FAERS

  18. Real-world safety assessment of burosumab: a pharmacovigilance study utilizing the FDA adverse event reporting system.

  ブロスマブのリアルワールドでの安全性をFAERSを用いて評価。

  対象DB：FAERS

  19. Assessing the real-world drug safety of sevelamer for hyperphosphatemia: Insights from a comprehensive analysis of the FDA adverse event reporting system (FAERS) database.

  セベラマーの安全性をFAERSで解析し、新規副作用を特定。

  対象DB：FAERS

  20. A real-world pharmacovigilance study of bempedoic acid plus ezetimibe fixed-dose combination based on the FDA FAERS database.

  FAERSを用いベムペド酸・エゼチミブ配合剤の副作用を解析。

  対象DB：FAERS

  21. Real-world safety of voretigene neparvovec: a disproportionality analysis for signal detection using the FAERS database.

  FAERSデータを用い、ボレチゲンネパルボベクの安全性を評価。

  対象DB：FAERS

  22. Real-world disproportionality analysis of trabectedin using the United States food and drug administration adverse event reporting system.

  トラベクテジンの副作用をFAERSで解析しシグナルを特定。

  対象DB：FAERS

  23. Thromboembolic events with olanzapine: a systematic review integrating meta-analysis and FAERS database.

  オランザピンの血栓塞栓症リスクを系統的レビュー等で解析。

  対象DB：FAERS

  24. Evaluating the real-world safety of cholestyramine for the treatment of hyperlipidemia: disproportionality analysis of FAERS data.

  コレスチラミンの副作用プロファイルをFAERSデータで解析。

  対象DB：FAERS

  25. Drugs Associated with Pediatric Cataracts: A Real-World Pharmacovigilance Study.

  小児白内障に関連する薬剤をFAERSデータベースを用いて特定。

  対象DB：FAERS

  26. Analysis of adverse event reporting with casimersen: a pharmacovigilance study based on the United States food and drug administration adverse event reporting system database.

  カシメルセンの副作用報告をFAERSに基づき系統的に解析。

  対象DB：FAERS

  27. Comparative analysis of adverse event reporting signals between Satralizumab and Inebilizumab in neuromyelitis optica spectrum disorder: A pharmacovigilance study using the FDA Adverse Event Reporting System.

  NMOSD治療薬2種の副作用シグナルをFAERSを用いて比較。

  対象DB：FAERS

  28. Adverse drug events and toxicological mechanisms of esketamine: a study based on US Food and Drug Administration Adverse Event Reporting System and network toxicology analysis.

  エスケタミンの副作用と毒性メカニズムをFAERS等で解析。

  対象DB：FAERS

  29. Predictors of Contrast Extravasation in the Emergency Department: A Case-Control Multi-Center Retrospective Study.

  救急外来における造影剤漏出の予測因子を多施設共同研究で調査。

  対象DB：FAERS

  30. Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.

  GLP-1受容体作動薬の自殺関連副作用を非GLP-1薬と比較。

  対象DB：FAERS

  31. [Drug related lipid metabolism abnormalities: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)].

  薬剤性脂質代謝異常のリスクをFAERSデータベースで解析。

  対象DB：FAERS

  32. Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study.

  GLP-1受容体作動薬の投与に伴う副作用を横断的研究で解析。

  対象DB：FAERS

  33. Comparison of Dermatologic and Neuropsychological Side Effects of Oral Contraceptives, 2016-2020.

  経口避妊薬による皮膚および神経心理学的副作用を比較調査。

  対象DB：FAERS

  34. Decoding tamoxifen on idiopathic pulmonary fibrosis: integrating network toxicology and multi-omics.

  タモキシフェンの特発性肺線維症への影響をオミクス解析で解明。

  対象DB：FAERS

  35. Drug-induced perioperative malignant hyperthermia: a real-world study based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database.

  薬剤性周術期悪性高熱症のリスクをFAERSデータに基づき解析。

  対象DB：FAERS

  36. Maternal and Pediatric Precision in Therapeutic Knowledge Portal (MPRINT-KP): Landscape Analysis of Pharmacology Research in Maternal and Pediatric Patient Populations.

  母子薬理学研究の現状をMPRINT-KPポータルを通じて解析。

  対象DB：FAERS

  37. Comparative safety of denosumab and romosozumab in osteoporosis: an analysis based on the FDA adverse event reporting system database.

  骨粗鬆症薬デノスマブとロモソズマブの安全性をFAERSで比較。

  対象DB：FAERS

  38. Revisiting Disproportionality: Prescription-Adjusted and TF-IDF-Inspired Metrics for Post-Market ADR Detection.

  処方調整指標を用いた市販後副作用検出精度の向上手法を提案。

  対象DB：FAERS

  39. Antihypertensives and skin cancer: Evidence from the FDA Adverse Event Reporting System.

  降圧薬と皮膚がんリスクの関連をFAERSデータに基づき解析。

  対象DB：FAERS

  40. Disproportionality analysis and "perpetrator" or "accomplice" review of Baloxavir marboxil in public FAERS database.

  バロキサビルの市販後安全性をFAERSデータベースで解析。

  対象DB：FAERS

  41. Potential protective role of GLP-1 receptor agonists for lithium-induced nephrotoxicity: a population-based observational study.

  GLP-1受容体作動薬のリチウム誘発性腎毒性保護効果を検討。

  対象DB：FAERS

  42. Infant deaths in the EudraVigilance database.

  EudraVigilanceを用いた乳児死亡例の記述的解析。

  対象DB：EudraVigilance

  43. Safety profile of fentanyl with different routes of administration: a disproportionality analysis using the EudraVigilance database.

  投与経路別フェンタニルの安全性プロファイルをFAERSで解析。

  対象DB：EudraVigilance

  44. Vigi4Eudra-score: Evaluation of the completeness of spontaneous adverse drug reaction reports in EudraVigilance.

  EudraVigilanceの副作用報告の網羅性を評価する指標を開発。

  対象DB：EudraVigilance,VigiBase

  45. Enhanced passive safety surveillance during the first use of the meningococcal vaccine A/C/W/Y/X conjugate for outbreak response in Niger and Nigeria.

  ガンビアにおける髄膜炎菌ワクチンの初回導入時の安全性監視。

  対象DB：VigiBase

  46. A pharmacovigilance data-driven approach to reveal high fatal adverse events following checkpoint immunotherapy.

  ICIとVEGFR-TKI併用後の致命的副作用をFAERSで解析。

  対象DB：VigiBase

  47. A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase.

  ニボルマブによる致命的転帰の高齢者と非高齢者間の比較。

  対象DB：VigiBase

  48. A study in VigiBase of clozapine fatal outcomes in 7874 middle-aged versus 4380 young adults.

  クロザピンによる致命的転帰の年齢層別比較をVigiBaseで解析。

  対象DB：VigiBase

  49. National cost of intensive care in Japan from 2018 to 2022.

  2018-22年の日本における集中治療の公的医療費を推計。

  対象DB：DPC

  50. Cost-effectiveness analysis of immune checkpoint inhibitors versus platinum-based doublet chemotherapy in the first-line treatment of advanced non-small-cell lung cancer with High PD-L1 expression in Japan.

  高齢肺がん患者への免疫療法と化学療法の費用対効果を比較。

  対象DB：DPC

  51. Return on investment of national specific health guidance in Japan: an observational study using "Wellness-Star small star, filled" health insurance claims database.

  日本の特定保健指導の投資収益率をレセプトデータから評価。

  対象DB：NDB

  52. Bipolar disorder in later life: lifestyle and physical health.

  高齢期における双極性障害のライフスタイルと身体的健康を調査。

  対象DB：CPRD

  53. Developing and Validating the CE-MACE Model to Predict One-Year Major Adverse Cardiovascular Events Post COPD Exacerbation Using Routine Healthcare Data.

  2型糖尿病併発冠疾患患者の1年後心血管事象予測モデルを構築。

  対象DB：CPRD

  54. Prognostic score for predicting respiratory admissions among patients with chronic obstructive pulmonary disease in primary care: development and validation in population cohorts (Birmingham Lung Improvement Studies (BLISS)).

  COPD患者の呼吸器関連入院を予測する予後スコアの開発。

  対象DB：CPRD

  55. Data Resource Profile: Prostate cancer data from Clinical Practice Research Datalink linked hospital records, mortality data and cancer registry standardized to the Observational Medical Outcomes Partnership common data model (CPRD-PCa-OMOP).

  CPRD等を用いた英国の前立腺がんデータのプロファイルを紹介。

  対象DB：CPRD

  56. The long-term impact of early HbA1c control on nephropathy, neuropathy, and retinopathy in type 2 diabetes: Findings from a large UK observational study.

  2型糖尿病の早期血糖管理が合併症に与える長期的影響を解析。

  対象DB：CPRD

  57. Population attributable fraction of modifiable risk factors for incident hypertension: an analysis of large-scale epidemiological cohort.

  高血圧発症における修正可能なリスク因子の人口寄与割合を解析。

  対象DB：DeSC

  58. Effects of smartphone cognitive behavioural therapy on social functioning in non-depressive and subthreshold depressive adults: a secondary analysis of the RESiLIENT trial.

  スマホCBTが社交不安症患者の社会的機能に与える影響を評価。

  対象DB：DeSC

  59. Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan.

  日本におけるリウマチ治療へのバイオシミラー導入促進策を解析。

  対象DB：DeSC

  60. Discontinuation of statins by patient and physician sex: An observational study.

  医師と患者の性別によるスタチン治療中断リスクの違いを調査。

  対象DB：DeSC

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み